Skip to main content

Table 1 Scan indications and demographic distribution of image evaluation group

From: Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body 18F-FDG PET/CT scans

Scan indication

Number of patients

Age distribution*

BMI*

Total

Male

Female

All

Male

Female

All

Male

Female

Breast Cancer

1

–

1

51

–

51

28.4

–

28.4

Cancer of unknown primary origin

3

1

2

68

87

58 [57–59]

29.7 [22.2–37.6]

22.2

33.65 [29.7–37.6]

Gastro–intestinal cancer

21

17

4

67 [29–83]

67 [29–83]

64 [44–75]

26.2 [16.8–40.6]

26.5 [16.8–40.6]

20.8 [18.9–27.6]

Head & Neck cancer

12

8

4

64.5 [32–81]

66 [53–81]

62.5 [32–66]

24.6 [22.6–37.4]

25.7 [22.8–36.5]

22.9 [22.6–37.4]

Infection & Inflammation

13

8

5

64 [21–89]

58.5 [27–78]

64 [21–89]

24.2 [20.7–36.8]

23.9 [20.7–36.8]

24.6 [21.9–26.4]

Lung Cancer

97

52

45

74 [42–89]

75 [42–86]

72 [42–89]

25.8 [14.5–44.4]

26 [14.5–42.6]

25.7 [16–44.4]

Lymphoma

23

14

9

67 [18–80]

62 [39–78]

67 [18–80]

25.3 [19.4–45.4]

27.2 [19.8–45.4]

23.7 [19.4–31.6]

Melanoma

10

5

5

62.5 [52–81]

64 [57–79]

60 [52–81]

27 [23.1–31.3]

27.1 [25.5–28.7]

26.8 [23.1–31.3]

NET

1

1

–

68

68

–

25.5

25.2

–

Sarcoma

1

–

1

63

–

63

32.5

–

32.5

Uro–genital cancer

18

2

16

65 [26–87]

63 [59–67]

66 [26–87]

25.8 [20.5–47.7]

33.5 [32.2–34.7]

24.2 [20.5–47.7]

Total

200

108

92

68 [18–89]

70 [27–87]

70 [18–89]

25.6 [14.5–47.7]

26.1 [14.5–45.4]

25.4 [16–47.7]

  1. *Values are median [range]